Sagility's AI growth strategy received a major boost after the healthcare services provider announced the acquisition of U.S.-based CareSeed, a company known for its healthcare quality analytics and HEDIS reporting solutions.
.jpeg)
India must stay attractive for innovation-led pharma investment as policy, IP protection and faster approvals remain critical to drive next-gen therapies and global clinical research.
The Navi Mumbai MediCity project has taken a major step forward with the Maharashtra government signing a Memorandum of Understanding (MoU) with Cleveland Clinic, Brookfield Asset Management, and Arodhan Health City.
Global race for generic semaglutide gains pace ahead of patent expiry, with Hetero-Richter partnership highlighting rising competition and export opportunities for India.
In an interaction with Thiruamuthan, Assistant Editor at India Pharma Outlook, Veerendra Kumar Reddy, General Manager, Enzene Biosciences, discusses how perfusion technology is transforming biologics manufacturing by improving productivity, reducing
Concord Biotech shares surged in trade on June 10 after the company received a major regulatory boost from the United States Food and Drug Administration (USFDA). The rally came after Concord Biotech secured approval for its Abbreviated New Drug...
India is strengthening global pharmaceutical partnerships to drive innovation, expand manufacturing, and accelerate healthcare growth, with the USD 60 billion industry aiming to double in size over five years.
India’s MedTech opportunity is emerging as a major growth driver for the country’s electronics manufacturing services (EMS) industry. As competition intensifies in consumer electronics manufacturing and margins remain under pressure, leading EMS...
Alembic Pharma announced its participation in a newly incorporated Canadian company focused on developing, commercializing, distributing, and marketing pharmaceutical products in Canada. The move marks another step in the company's international...
Mumbai-based pharmaceutical company Lupin Limited has received U.S. FDA approval for Ranluspec biosimilar (ranibizumab-hkdz), a biosimilar to Lucentis used in the treatment of serious eye conditions. The approval marks an important step in Lupin...
.jpg)
, CDSCO.jpg)